Elasmogen is a brand that is revolutionizing the life science industry with its innovative products and services. Led by a team of experienced professionals, including Dr. Jane Dancer and Professor Caroline Barelle, Elasmogen is dedicated to developing biologics and biotherapeutic technologies to address a wide range of medical needs.

With a strong focus on commercialization and bio-partnering, Elasmogen has successfully progressed early platform technologies to late-stage clinical development. Their extensive patent portfolio and IP strategy, managed by Professor Andy Porter, ensures that their products remain at the forefront of the industry. Elasmogen offers a diverse range of diagnostic and therapeutic targets, including oncology, inflammation, CNS disease, and even Covid-19.

Their cutting-edge technologies have the potential to transform the way we approach healthcare. Supported by investor directors Savvas Neophytou and Keith Barclay, Elasmogen is committed to driving innovation and creating value in the life science sector. With their expert management team, including Vice Principal of Research & Development Dr.

Rob Boyd, Elasmogen is poised to lead the way in groundbreaking advancements in medicine. Trust Elasmogen to deliver groundbreaking solutions that will shape the future of healthcare